Engineering a microneedle patch for opioid overdose therapy
Files
TR Number
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The opioid overdose epidemic, exacerbated by potent synthetic opioids such as fentanyl, presents a critical challenge to public health. Naloxone hydrochloride, a μ-opioid receptor antagonist, is the frontline therapeutic for overdose reversal; however, its clinical utility is constrained by rapid clearance, frequent re-dosing requirements, and complications associated with conventional delivery methods. In this work, we developed a minimally invasive microneedle (MN) patch system using gelatin methacryloyl (GelMA) hydrogels to enable sustained transdermal delivery of naloxone. Microneedle arrays (10×10, 600 µm height, 500 µm pitch) were fabricated with tunable UV crosslinking (0s, 15s, 30s, 60s) to optimize their physicochemical properties. Results indicated that 60s-crosslinked GelMA MNs exhibited enhanced mechanical strength, reduced enzymatic degradation (34.03% at 360 min), and a prolonged drug release profile (81.6% release over 24 h), verified via HPLC. Histological assessment in murine skin confirmed successful dermal penetration with crosslinked MNs. Furthermore, fluorescence imaging of fentanyl-treated HEK293T cells demonstrated functional naloxone antagonism, as evidenced by a time-dependent reduction in opioid-induced fluorescence. This study highlights GelMA-based microneedles as a robust and adaptable platform for opioid antagonist delivery. By modulating crosslinking parameters, the device achieves customizable release kinetics to counteract both immediate and long-duration overdose threats. This platform offers a promising alternative to injection-based therapies, with translational potential for point-of-care and community-level overdose management.